SG43030A1 - Method of treating hyperproliferative vascular disease - Google Patents

Method of treating hyperproliferative vascular disease

Info

Publication number
SG43030A1
SG43030A1 SG1996002641A SG1996002641A SG43030A1 SG 43030 A1 SG43030 A1 SG 43030A1 SG 1996002641 A SG1996002641 A SG 1996002641A SG 1996002641 A SG1996002641 A SG 1996002641A SG 43030 A1 SG43030 A1 SG 43030A1
Authority
SG
Singapore
Prior art keywords
vascular disease
treating hyperproliferative
hyperproliferative vascular
treating
rapamycin
Prior art date
Application number
SG1996002641A
Other languages
English (en)
Inventor
Stephen Skwish
Robert Dempster Mitchell
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/874,895 external-priority patent/US5288711A/en
Priority claimed from GB929217630A external-priority patent/GB9217630D0/en
Application filed by American Home Prod filed Critical American Home Prod
Publication of SG43030A1 publication Critical patent/SG43030A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG1996002641A 1992-04-28 1993-04-27 Method of treating hyperproliferative vascular disease SG43030A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/874,895 US5288711A (en) 1992-04-28 1992-04-28 Method of treating hyperproliferative vascular disease
GB929217630A GB9217630D0 (en) 1992-08-19 1992-08-19 Method of treating hyperproliferative vascular disease

Publications (1)

Publication Number Publication Date
SG43030A1 true SG43030A1 (en) 1997-10-17

Family

ID=26301459

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996002641A SG43030A1 (en) 1992-04-28 1993-04-27 Method of treating hyperproliferative vascular disease

Country Status (15)

Country Link
EP (1) EP0568310B1 (hu)
JP (1) JP2550277B2 (hu)
KR (1) KR100284210B1 (hu)
AT (1) ATE135226T1 (hu)
AU (1) AU670937B2 (hu)
BR (1) BR9301667A (hu)
CA (1) CA2094858C (hu)
DE (1) DE69301754T2 (hu)
DK (1) DK0568310T3 (hu)
ES (1) ES2085720T3 (hu)
GR (1) GR3019380T3 (hu)
HK (1) HK109097A (hu)
HU (1) HU215388B (hu)
SG (1) SG43030A1 (hu)
TW (1) TW224051B (hu)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435318D1 (de) 1993-01-28 2010-12-09 Boston Scient Ltd Therapeutische inhibitoren der zellen der glatten gefässmuskulatur
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5620687A (en) * 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
NZ511762A (en) 1993-07-19 2003-09-26 Univ British Columbia Anti-angiogenic compositions and methods of use
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
WO1995014023A1 (en) * 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5618837A (en) * 1995-06-07 1997-04-08 Zymogenetics, Inc. PDGF antagonists III
CZ292233B6 (cs) 1995-06-09 2003-08-13 Novartis Ag Deriváty rapamycinu a jejich použití jako léčiv
WO1997002036A1 (en) * 1995-06-30 1997-01-23 Zymogenetics, Inc. 4-(2-(n-2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas as pdgf antagonists
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
IT1289815B1 (it) 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7445792B2 (en) 2003-03-10 2008-11-04 Abbott Laboratories Medical device having a hydration inhibitor
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US8029561B1 (en) 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) * 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
WO2001001957A1 (en) * 1999-05-27 2001-01-11 Biocompatibles Limited Local drug delivery
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
DE60114406T2 (de) * 2000-05-12 2006-08-03 Cordis Corp., Miami Lakes Wirkstoffabgabesysteme zur behandlung von gefässerkrankungen
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
AU2005202474B2 (en) * 2000-05-12 2007-09-06 Cardinal Health 529, Llc Delivery devices for treatment of vascular disease
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US6746773B2 (en) 2000-09-29 2004-06-08 Ethicon, Inc. Coatings for medical devices
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
WO2002026139A1 (en) * 2000-09-29 2002-04-04 Cordis Corporation Coated medical devices
AU1129902A (en) * 2000-09-29 2002-04-08 Cordis Corp Coated medical devices
ATE387169T1 (de) 2000-10-16 2008-03-15 Conor Medsystems Inc Expandierbare medizinische vorrichtung zum zuführen eines heilmittels
US8182527B2 (en) 2001-05-07 2012-05-22 Cordis Corporation Heparin barrier coating for controlled drug release
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
JP2005533604A (ja) * 2002-07-25 2005-11-10 アバンテック バスキュラー コーポレーション 治療薬を送達する装置とこれに関する方法
US7438925B2 (en) * 2002-08-26 2008-10-21 Biovention Holdings Ltd. Drug eluting coatings for medical implants
US8791171B2 (en) 2003-05-01 2014-07-29 Abbott Cardiovascular Systems Inc. Biodegradable coatings for implantable medical devices
EP2329852A1 (en) 2004-03-26 2011-06-08 SurModics, Inc. Composition and method for preparing biocompatible surfaces
EP1735024A1 (en) 2004-03-26 2006-12-27 SurModics, Inc. Process and systems for biocompatible surfaces
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
CA2656635C (en) 2006-07-03 2013-05-28 Hemoteq Ag Stent with polymeric coating comprising rapamycin as an active agent
US9028859B2 (en) 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
RU2447901C2 (ru) 2007-01-21 2012-04-20 Хемотек Аг Медицинский продукт для лечения обтураций просветов организма и для предупреждения угрожающих повторных обтураций
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US20090074831A1 (en) * 2007-09-18 2009-03-19 Robert Falotico LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS
WO2009089549A1 (en) 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
EP3064230B1 (en) 2009-07-10 2019-04-10 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
WO2011008393A2 (en) 2009-07-17 2011-01-20 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
US8889211B2 (en) 2010-09-02 2014-11-18 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
US8669360B2 (en) 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
US9056152B2 (en) 2011-08-25 2015-06-16 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating

Also Published As

Publication number Publication date
EP0568310A1 (en) 1993-11-03
DE69301754T2 (de) 1996-08-08
BR9301667A (pt) 1993-11-03
JP2550277B2 (ja) 1996-11-06
HK109097A (en) 1997-08-22
ATE135226T1 (de) 1996-03-15
CA2094858A1 (en) 1993-10-29
GR3019380T3 (en) 1996-06-30
AU3713693A (en) 1993-11-04
HU215388B (hu) 1998-12-28
HU9301216D0 (en) 1993-07-28
AU670937B2 (en) 1996-08-08
KR940005280A (ko) 1994-03-21
DK0568310T3 (da) 1996-07-29
JPH0680573A (ja) 1994-03-22
KR100284210B1 (ko) 2001-03-02
TW224051B (hu) 1994-05-21
HUT64231A (en) 1993-12-28
EP0568310B1 (en) 1996-03-13
ES2085720T3 (es) 1996-06-01
DE69301754D1 (de) 1996-04-18
CA2094858C (en) 2004-06-15

Similar Documents

Publication Publication Date Title
SG43030A1 (en) Method of treating hyperproliferative vascular disease
SG47639A1 (en) Method of treating hyperproliferative vascular disease
SG47786A1 (en) Method of treating crohn's disease ulcerative colitis or ulcerative proctitis
EP0746314A4 (en) METHOD FOR TREATING HYPERPROLIFERATIVE VASICAL DISEASE
IL108455A0 (en) Vascular and coronary stents
AU1791895A (en) Method of preventing hyperproliferative vascular disease
AU1091095A (en) Intraluminal vascular graft and method
GB9309397D0 (en) Laser treatment
GB9207808D0 (en) Vascular graft apparatus
GB9512452D0 (en) A prosthetic vascular graft
EP0710106A4 (en) METHOD FOR TREATING ADDICTIVE BEHAVIOR
GB9217630D0 (en) Method of treating hyperproliferative vascular disease
ZA948377B (en) Smoking articles and method of making them.
PH31412A (en) Method of treating septic shock using thymosin-alpha 1.
GB9300426D0 (en) Vascular grafts
GB9325612D0 (en) Vascular grafts
GB9302515D0 (en) Vascular stent
GB9205620D0 (en) Vascular grafts
EP0608702A3 (de) Verfahren zum Behandeln von Haselnüssen.
GB9606880D0 (en) Vascular prostheses
GB9320288D0 (en) Vascular prostheses
EP0932406A4 (en) METHODS OF TREATING OR PREVENTING INTERSTITIAL CYSTITIS
GB9201316D0 (en) Pin and track retainer
IE901550L (en) Treating thrombosis
LTIP1423A (en) Device for treatment of gullet stricture